Skip To Content
Get Our Newsletter
JEWISH. INDEPENDENT. NONPROFIT.

Support the Forward

Funded by readers like you DonateSubscribe
Breaking News

Myriad Genetics Stock Plunges After Supreme Court Loss

The stock of Myriad Genetics plunged after the Supreme Court rejected its effort to patent a human gene mutation that is linked to cancer and is common among Ashkenazi Jews.

Shares of the biotech company dropped about 15% on Friday after spiraling up by about 10% on Thursday.

The stock initially rocketed up by more than 10% in the hours after the Supreme Court decision was announced. Initial reports put a positive spin on the decision’s potential effects on the company’s lucrative effort to corner the market on the BRCA-1 gene mutation that leads to a higher risk of breast cancer.

But as more information emerged about the unanimous ruling, it gave back the gains and turned sharply negative.

Analysts say other companies may now enter the market for testing for the mutation, which may lower the price of the tests and sharply reduce Myriad’s profits.

The company’s stock had soared last month when Hollywood superstar Angelina Jolie announced she underwent a double mastectomy to avoid the risk of breast cancer related to the BRCA1 defect.

At that time, analysts pointed out that Jolie’s star power would likely spur more women to undergo the tests, which would in turn boost Myriad’s revenue.

Engage

  • SHARE YOUR FEEDBACK

  • UPCOMING EVENT

    NY-12 Candidate Forum

    THE TEMPLE EMANU-EL STREICKER CENTER and Virtual

    Aug 10, 2022

    7 pm ET · 

    Will the last Jew left in New York’s congressional delegation be reelected? Will New York’s senior congresswoman receive another term? Or will one of the newcomers upend Manhattan politics?

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free under an Attribution-Non Commercial-No Derivatives Creative Commons license as long as you follow our republishing guidelines, which require that you credit the Foward and retain our pixel. See our full guidelines for more information.

To republish, copy the HTML, which includes our tracking pixel, all paragraph styles and hyperlinks, the author byline, images, and credit to the Foward. Have questions? Please email us at editorial@forward.com.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.